



INTERGENETICS NAMED 'INNOVATOR OF THE YEAR'

Company Receives Award for World's First Genetic-Based Breast Cancer Risk Prediction Test - ONCOVUE

OKLAHOMA CITY, April 11, 2005—InterGenetics, an Oklahoma City-based genetic cancer risk intervention company, was named recipient of the '2005 *Journal Record* Innovator of the Year Award' for its lead product, OncoVue. OncoVue™ is the world's first breast cancer risk predictive test that can determine the lifetime and age-specific risk of developing breast cancer for all women.

In presenting the top award to InterGenetics, *Journal Record* publisher Mary Melon said, "Innovation is the cornerstone of economic growth and vitality. Companies such as InterGenetics represent the kind of imagination, ingenuity and dedication that will continue to push Oklahoma to the forefront."

"Winning Innovator of the Year for Oklahoma is an honor and validates the breakthrough potential OncoVue has as the next-generation breast cancer risk test in the national marketplace," said Dr. Craig Shimasaki, InterGenetics CEO and President. "Such an award gives us new momentum as we enter the final phase of our business plan, accelerating towards commercial launch of OncoVue this fall."

"Few breast cancers are familial, the kind that are identified by having a strong family history of breast cancer," said Dr. Shimasaki. "In fact, 90% of women who get breast cancer do not have a mother, sister or daughter with the disease. These are the types of individuals that OncoVue can help".

The OncoVue test is easy for a woman to perform. First, she answers a simple medical history questionnaire, then swishes a harmless mouthwash and deposits the fluid into a tube. In the laboratory, DNA from the woman's cheek cells is analyzed, along with the data from the medical questionnaire, to assign a numeric score that represents her risk of developing breast cancer for every five years of her life.

"By knowing her risk level, a woman can take preventative medications to reduce the occurrence of the disease, or be screened with more comprehensive screening tools to catch breast cancer at its earliest stages, where long-term survival is the greatest – or simply have a new peace of mind," added Dr. Shimasaki.

OncoVue is different from other genetic risk assessment tests because InterGenetics' scientists have discovered that combinations of genes, along with personal history, help determine a more complete genetic picture of breast cancer susceptibility by looking at interactions of genes that impact risk rather than the limited picture any single gene can offer.

About InterGenetics

InterGenetics, a genetics-based cancer-risk testing and cancer treatment company is emerging as an innovator in the frontier of genetic medicine. The company's lead product, the OncoVue™ Breast Cancer Risk Test, uses proprietary gene combinations and DNA assessment technology developed by InterGenetics' scientists to quickly and accurately identify women who are at high risk of developing breast cancer, potentially many years in advance of their diagnosis.

InterGenetics has a promising research pipeline of predictive tests for other cancers such as ovarian, colon, prostate, and pancreatic cancer. The company's core research has future application in also predicting heart disease, diabetes and in enhancing the effectiveness of drug therapies and preventative medicine in these fields. www.intergenetics.com

For More Information Contact: Jane Braden 405 715-3232